Company intelligence / Profile preview

T-ACE Medical

Ownership: Private
Development stage: Other

Overview

T-ACE Medical has developed three main products focused on minimally invasive interventional therapies for gastroenterology and oncology. AceGel facilitates endoscopic removal of GI lesions. T‑ACE Oil serves as an embolic agent in transarterial chemoembolization (TACE) for liver cancer. T‑ACE Beads are next-generation drug-eluting beads also used in liver cancer therapy via the same procedure. The company leverages clinical experience to address unmet needs with effective yet affordable solutions.

Therapeutic areas: GastroenterologyOncology
Modalities: DeviceDrug-device combination
Industry: Therapeutic Medical Devices

Partnerships

Joint venture with Food Industry Research & Development Institute

Beyond the preview

Go deeper on T-ACE Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-ACE Medical.

Explore the full profile